Next Article in Journal
miR-21 Plays a Dual Role in Tumor Formation and Cytotoxic Response in Breast Tumors
Next Article in Special Issue
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
Previous Article in Journal
Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma
Previous Article in Special Issue
Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
Open AccessReview

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

1
Mannheim University Medical Center, University of Heidelberg, 68167 Mannheim, Germany
2
National LeioMyoSarcoma Foundation (NLMSF), Denver, CO 80222, USA
3
Sarcoma Patients EuroNet, SPAEN, 61200 Wölfersheim, Germany
4
Department of Surgery, Mount Sinai Hospital, Toronto, ON M5G 1XS, Canada
5
Dana-Farber Cancer Institute, Boston, MA 02215, USA
6
Institute of Cancer Research, London SM2 5NG, UK
7
Department of Medicine, Columbia University School of Medicine, New York, NY 10032, USA
8
Royal Marsden Hospital, London SW3 6JJ, UK
9
Northwestern Medicine, Feinberg School of Medicine, Chicago, IL 60611, USA
10
Sarcoma Alliance for Research through Collaboration (SARC), Ann Arbor, MI 48105, USA
11
Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
12
Michigan Medicine Sarcoma Clinic, Rogel Cancer Center, Ann Arbor, MI 48109, USA
13
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Care Center, Houston, TX 77030, USA
14
Barnes and Jewish Hospital, Washington University in St. Louis, St. Louis, MO 63110, USA
15
Department of Sarcoma Medical Oncology, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA
16
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
17
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Justus P. Beier
Cancers 2021, 13(4), 886; https://doi.org/10.3390/cancers13040886
Received: 29 January 2021 / Revised: 11 February 2021 / Accepted: 15 February 2021 / Published: 20 February 2021
(This article belongs to the Special Issue New Directions for Treating Soft Tissue Sarcomas)
In this position paper, we aim to summarize state-of-the-art treatments for patients with leiomyosarcomas in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This white paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).
As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN. View Full-Text
Keywords: leiomyosarcoma; NLMSF; SPAEN; treatment; research leiomyosarcoma; NLMSF; SPAEN; treatment; research
Show Figures

Figure 1

MDPI and ACS Style

Kasper, B.; Achee, A.; Schuster, K.; Wilson, R.; van Oortmerssen, G.; Gladdy, R.A.; Hemming, M.L.; Huang, P.; Ingham, M.; Jones, R.L.; Pollack, S.M.; Reinke, D.; Sanfilippo, R.; Schuetze, S.M.; Somaiah, N.; Van Tine, B.A.; Wilky, B.; Okuno, S.; Trent, J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers 2021, 13, 886. https://doi.org/10.3390/cancers13040886

AMA Style

Kasper B, Achee A, Schuster K, Wilson R, van Oortmerssen G, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers. 2021; 13(4):886. https://doi.org/10.3390/cancers13040886

Chicago/Turabian Style

Kasper, Bernd; Achee, Annie; Schuster, Kathrin; Wilson, Roger; van Oortmerssen, Gerard; Gladdy, Rebecca A.; Hemming, Matthew L.; Huang, Paul; Ingham, Matthew; Jones, Robin L.; Pollack, Seth M.; Reinke, Denise; Sanfilippo, Roberta; Schuetze, Scott M.; Somaiah, Neeta; Van Tine, Brian A.; Wilky, Breelyn; Okuno, Scott; Trent, Jonathan. 2021. "Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)" Cancers 13, no. 4: 886. https://doi.org/10.3390/cancers13040886

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop